Which has better valuation and earnings, PODD or DXCM?

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.66 $247.10M $4.30 33.32 DexCom $4.82B 5.79 $836.30M $2.34 30.91

Is PODD or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% DexCom 19.31% 33.33% 13.19%

Does the media refer more to PODD or DXCM?

In the previous week, DexCom had 8 more articles in the media than Insulet. MarketBeat recorded 22 mentions for DexCom and 14 mentions for Insulet. DexCom's average media sentiment score of 1.25 beat Insulet's score of 0.19 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 20 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, RMD or PODD?

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.54B 5.00 $1.40B $10.37 18.39 Insulet $2.71B 3.66 $247.10M $4.30 33.32

Is RMD or PODD more profitable?

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Insulet 10.44% 26.87% 12.01%

Does the media refer more to RMD or PODD?

In the previous week, ResMed had 8 more articles in the media than Insulet. MarketBeat recorded 22 mentions for ResMed and 14 mentions for Insulet. ResMed's average media sentiment score of 1.44 beat Insulet's score of 0.19 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, STE or PODD?

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.48 $782.30M $7.93 26.59 Insulet $2.71B 3.66 $247.10M $4.30 33.32

Is STE or PODD more profitable?

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.18% 14.15% 9.52% Insulet 10.44% 26.87% 12.01%

Does the media refer more to STE or PODD?

In the previous week, Insulet had 8 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Insulet and 6 mentions for STERIS. STERIS's average media sentiment score of 1.68 beat Insulet's score of 0.19 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insulet 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, GMED or PODD?

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.62 $537.87M $4.30 18.25 Insulet $2.71B 3.66 $247.10M $4.30 33.32

Is GMED or PODD more profitable?

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% Insulet 10.44% 26.87% 12.01%

Does the media favor GMED or PODD?

In the previous week, Insulet had 10 more articles in the media than Globus Medical. MarketBeat recorded 14 mentions for Insulet and 4 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.33 beat Insulet's score of 0.19 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insulet 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BAX or PODD?

In the previous week, Insulet had 11 more articles in the media than Baxter International. MarketBeat recorded 14 mentions for Insulet and 3 mentions for Baxter International. Insulet's average media sentiment score of 0.19 beat Baxter International's score of 0.00 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baxter International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insulet 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Insulet (PODD) Competitors

$144.07 +1.64 (+1.15%)

As of 10:14 AM Eastern

Compare

PODD vs. DXCM, RMD, STE, GMED, and BAX

Should you buy Insulet stock or one of its competitors? MarketBeat compares Insulet with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insulet include DexCom (DXCM), ResMed (RMD), STERIS (STE), Globus Medical (GMED), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.

How does Insulet compare to DexCom?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Insulet presently has a consensus target price of $252.04, indicating a potential upside of 75.93%. DexCom has a consensus target price of $82.42, indicating a potential upside of 13.93%. Given Insulet's higher probable upside, analysts clearly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

Insulet has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

In the previous week, DexCom had 8 more articles in the media than Insulet. MarketBeat recorded 22 mentions for DexCom and 14 mentions for Insulet. DexCom's average media sentiment score of 1.25 beat Insulet's score of 0.19 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	20 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
DexCom	19.31%	33.33%	13.19%

97.8% of DexCom shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.66	$247.10M	$4.30	33.32
DexCom	$4.82B	5.79	$836.30M	$2.34	30.91

Summary

DexCom beats Insulet on 12 of the 17 factors compared between the two stocks.

How does Insulet compare to ResMed?

ResMed (NYSE:RMD) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

ResMed presently has a consensus price target of $286.18, indicating a potential upside of 50.04%. Insulet has a consensus price target of $252.04, indicating a potential upside of 75.93%. Given Insulet's stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74

In the previous week, ResMed had 8 more articles in the media than Insulet. MarketBeat recorded 22 mentions for ResMed and 14 mentions for Insulet. ResMed's average media sentiment score of 1.44 beat Insulet's score of 0.19 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

ResMed has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

55.0% of ResMed shares are held by institutional investors. 0.7% of ResMed shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.54B	5.00	$1.40B	$10.37	18.39
Insulet	$2.71B	3.66	$247.10M	$4.30	33.32

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Insulet	10.44%	26.87%	12.01%

Summary

ResMed beats Insulet on 11 of the 17 factors compared between the two stocks.

How does Insulet compare to STERIS?

STERIS (NYSE:STE) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

94.7% of STERIS shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.4% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.48	$782.30M	$7.93	26.59
Insulet	$2.71B	3.66	$247.10M	$4.30	33.32

In the previous week, Insulet had 8 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Insulet and 6 mentions for STERIS. STERIS's average media sentiment score of 1.68 beat Insulet's score of 0.19 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insulet	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

STERIS has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Insulet	10.44%	26.87%	12.01%

STERIS presently has a consensus target price of $278.00, indicating a potential upside of 31.85%. Insulet has a consensus target price of $252.04, indicating a potential upside of 75.93%. Given Insulet's higher probable upside, analysts clearly believe Insulet is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74

Summary

STERIS and Insulet tied by winning 8 of the 16 factors compared between the two stocks.

How does Insulet compare to Globus Medical?

Globus Medical (NYSE:GMED) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

95.2% of Globus Medical shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 0.4% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Globus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
Insulet	10.44%	26.87%	12.01%

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.62	$537.87M	$4.30	18.25
Insulet	$2.71B	3.66	$247.10M	$4.30	33.32

Globus Medical currently has a consensus price target of $106.36, suggesting a potential upside of 35.56%. Insulet has a consensus price target of $252.04, suggesting a potential upside of 75.93%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74

In the previous week, Insulet had 10 more articles in the media than Globus Medical. MarketBeat recorded 14 mentions for Insulet and 4 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.33 beat Insulet's score of 0.19 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insulet	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Globus Medical and Insulet tied by winning 8 of the 16 factors compared between the two stocks.

How does Insulet compare to Baxter International?

Baxter International (NYSE:BAX) and Insulet (NASDAQ:PODD) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Baxter International has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Insulet has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.32B	0.86	-$957M	-$2.13	N/A
Insulet	$2.71B	3.66	$247.10M	$4.30	33.32

Insulet has a net margin of 10.44% compared to Baxter International's net margin of -9.70%. Insulet's return on equity of 26.87% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.70%	16.15%	5.24%
Insulet	10.44%	26.87%	12.01%

In the previous week, Insulet had 11 more articles in the media than Baxter International. MarketBeat recorded 14 mentions for Insulet and 3 mentions for Baxter International. Insulet's average media sentiment score of 0.19 beat Baxter International's score of 0.00 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insulet	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.2% of Baxter International shares are held by institutional investors. 0.2% of Baxter International shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Baxter International currently has a consensus target price of $19.73, suggesting a potential upside of 5.10%. Insulet has a consensus target price of $252.04, suggesting a potential upside of 75.93%. Given Insulet's stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74

Summary

Insulet beats Baxter International on 14 of the 16 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PODD vs. The Competition

Export

Metric	Insulet	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.92B	$7.95B	$6.24B	$12.48B
Dividend Yield	N/A	2.56%	2.69%	5.30%
P/E Ratio	33.32	15.41	21.09	24.35
Price / Sales	3.66	5.78	561.45	126.00
Price / Cash	23.43	17.23	42.31	57.88
Price / Book	6.65	3.53	9.95	6.72
Net Income	$247.10M	$224.05M	$3.56B	$337.08M
7 Day Performance	-1.88%	-1.06%	-0.07%	1.63%
1 Month Performance	-18.16%	0.32%	5.08%	6.29%
1 Year Performance	-55.68%	0.45%	28.39%	35.50%

Insulet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PODD Insulet	4.1373 of 5 stars	$144.07 +1.2%	$252.04 +74.9%	-56.2%	$9.98B	$2.71B	33.50	5,400	Analyst Forecast
DXCM DexCom	4.4524 of 5 stars	$74.87 +1.5%	$82.42 +10.1%	-14.1%	$28.45B	$4.66B	32.00	11,000	Positive News Analyst Forecast
RMD ResMed	4.8934 of 5 stars	$186.58 -2.1%	$286.18 +53.4%	-25.0%	$27.64B	$5.15B	17.99	10,600	Positive News
STE STERIS	4.7849 of 5 stars	$210.80 -0.9%	$278.00 +31.9%	-13.2%	$20.86B	$5.94B	26.58	17,787	Positive News
GMED Globus Medical	4.0921 of 5 stars	$79.78 -2.6%	$106.36 +33.3%	+32.8%	$11.11B	$3.10B	18.55	6,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PODD) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insulet (PODD) Competitors